" class="no-js "lang="en-US"> Abacus Medicine & Laboratoires CTRS Improve Orphacol Access
Thursday, June 08, 2023

Abacus Medicine Pharma Services and Laboratoires CTRS Extend Partnership to Improve Access to Orphacol® in Spain

Abacus Medicine Pharma Services (AMPS) and Laboratoires CTRS, marketing authorization holder of Orphacol®, are proud to announce a strategic partnership that ensures continuous stock of Orphacol® in Spain. Furthermore, the partnership means improved delivery lead times for customers as well as implementation of simplified sales, distribution, and administration processes for Laboratoires CTRS, thus saving individual deliveries and the associated administration.

Orphacol® is a pharmaceutical product containing cholic acid, a substance found in the bile, which is used to digest fats. Orphacol® is used to treat adults and children who suffer from Bile Acid Synthesis Disorders (BASD), a genetic abnormality that makes them unable to produce bile.

Simon Estcourt, Managing Director of Abacus Medicine Pharma Services explains: “I am very proud of the partnership agreement between Abacus Medicine Pharma Services and Laboratoires CTRS. Our ambition is to provide better access to medicines and better healthcare to patients around the world. This partnership with Laboratoires CTRS will ensure reliable availability to Orphacol® in Spain at all times, as well as improved delivery time for customers.”

Franck Hamalian, President of Laboratoires CTRS states: “With this partnership, CTRS and AMPS, reduce lead time for delivery and further enhance availability of Orphacol® for patients in need on the Spanish territory. We know this to be a factor of highest importance for the life-saving treatment that is Orphacol® and are glad to join forces with such a robust and growing actor as AMPS.”

BASD are a group of rare metabolic disorders caused by a lack of various liver enzymes involved in the synthesis of bile acids. This makes the liver unable to produce enough of the main components of bile such as cholic acid. BASD are responsible for 1-2% of cases of neonatal cholestasis that occurs in approximately 1 in 2,500 births and is the main cause of liver-related paediatric hospitalisations as well as 80% of paediatric liver transplantations.

  1. Mendus and NorthX Biologics to Enter into Strategic Cell Therapy Manufacturing Alliance Supported by New Investor Flerie Read more
  2. SciTech Development Raises $2.73 Million in Oversubscribed Funding Round to Advance Clinical Trials for Cancer Treatment Read more
  3. Amarna Therapeutics Announces Appointment of Dr. Henk Streefkerk as New CEO Read more
  4. Aegis Life Awarded Grant to Develop DNA-encoded Antibodies Against Infectious Diseases Read more
  5. New “AI Doctor” Predicts Hospital Readmission and Other Health Outcomes Read more